by NanoVation | Dec 17, 2021 | 2021, 2021, News, Publications
Publication Dr. Arpan Desai publishes in SMALL on mechanistic studies of an automated LNP Mechanistic Studies of an Automated Lipid Nanoparticle Reveal Critical Pharmaceutical Properties Associated with Enhanced mRNA Functional Delivery In Vitro and In Vivo Cui et al....
by NanoVation | Aug 10, 2021 | 2021, 2021, News, Publications
Publication NTx scientists publish in American J. of Physiol. FAM13A as potential therapeutic target in modulating TGF-beta-induced airway tissue remodeling in COPD | AJP-Lung Cellular and Molecular Physiology Tam et al. 10 August 2021 Featuring Drs. Anthony Tam,...
by NanoVation | Jul 30, 2021 | 2021, News
News CIHR highlights role of LNPs in COVID vaccines In a multi-media feature on its website, the Canadian Institutes for Health Research (CIHR) has highlighted the role of NTx Co-Founder and Board Chair Dr. Pieter Cullis in developing the lipid nanoparticle (LNP)...
by NanoVation | Jul 1, 2021 | 2021, News
News NTx Co-Founder Dr. Pieter Cullis interviewed on CBC On 11 June 2021, NTx Co-Founder Dr. Pieter Cullis was interviewed on CBC radio about the core role played in mRNA-based COVID vaccines by the LNP technology he developed in his UBC lab. From the CBC website:...
by NanoVation | Jun 8, 2021 | 2021, 2021, News, Publications
Publication NTx’s Dr. Jayesh Kulkarni publishes in Langmuir on scalable production of LNPs with Amphotericin B Scalable Production of Lipid Nanoparticles Containing Amphotericin B Kulkarni et al. Langmuir 08 June 2021 Featuring Dr. Jayesh A Kulkarni from...
by NanoVation | May 31, 2021 | 2021, 2021, News, Publications
Publication NTx Co-Founders publish on current landscape of nucleic acid therapeutics The current landscape of nucleic acid therapeutics Kulkarni, Witzigmann et al. 31 May 2021 Featuring Drs. Jayesh A Kulkarni, Dominik Witzigmann and Pieter R Cullis from NanoVation...
